warrants currently exercisable or convertible, or exercisable or convertible within 60 days of the filing date of this proxy statement. However, we did not deem such shares outstanding for the purpose of computing the percentage ownership of any other person.
(2)
Consists of (i) 12,189 shares of Common Stock held by Dr. Boynton.Boynton and (ii) 2,481,301 shares of Common Stock underlying Options held by Dr. Boynton as equity compensation that are vested, or will vest within 60 days of this filing. An aggregate of 2,339,513 of the Options (which are included in the foregoing 2,481,301 Options) are currently vested and immediately exercisable for the purchase of Common Stock at an exercise price of $0.25 per share, and an additional 1,063,422 Options held by Dr. Boynton will vest monthly over a period of 24 months from the date of initial issuance, becoming exercisable for the purchase of Common Stock on the same terms, after they have vested.
(3)
Consists of (i) 9,802 shares of Common Stock held by Dr. Bosch and (ii) 141,2415,930,952 shares of Common Stock underlying optionsOptions held by Dr. Bosch as equity compensation that are vested, or will vest within 60 days of this filing. An aggregate of 5,458,871 of the Options (which are included in the foregoing 5,930,952 Options) are currently exercisable.vested and immediately exercisable for the purchase of Common Stock at an exercise price of $0.25 per share, and an additional 2,481,311 Options held by Dr. Bosch will vest monthly over a period of 24 months from the date of initial issuance, becoming exercisable for the purchase of Common Stock on the same terms, after they have vested.
(4)
Consists of (i) 5,072,2005,072,000 shares of Common Stock held by Ms. Powers; (ii) 804,145 shares of Common Stock held by Toucan Capital Fund III, L.P.;, (iii) 2,211,784 shares of Common Stock held by Toucan Partners, LLC; Ms. Powers has voting and dispositive power over the securities owned by the Toucan entities, and (iv) 592,50017,742,500 shares of Common Stock underlying options held by Ms. Powers as equity compensation that are currently exercisable. Ms. Powers’ beneficial ownership excludes anvested, or will vest within 60 days of this filing. An aggregate of 15,925,000 of the Options (which are included in the foregoing 17,742,500 Options) are currently vested and immediately exercisable for the purchase of Common Stock at an exercise price of $0.23 per share, and an additional 13,475,000 Options held by Ms. Powers will vest monthly over a period of 24 months from the date of initial issuance, becoming exercisable for the purchase of Common Stock on the same terms, after they have vested, (v) 2,591,176 shares of Series A Preferred Stock, convertible into 25,911,760 shares of common stock, and Class D-1 Warrants to acquire an aggregate of up to 25,911,76029,411,760 additional shares of Common Stock owned by Ms. Powers subject to certain conditions and limitations on conversion and exercisability, respectively. Ms. Powers’ beneficial ownership also excludes (i)(vi) 8,695,652 Class D-2 Warrants to acquire up to an aggregate of 86,956,5208,695,652 shares of Common Stock, issued in connection with a note and loan agreement dated March 14, 2018 between the Company and Ms. Powers, and (ii)(vii) 869,565 Class D-2 Warrants to acquire up to an aggregate of 8,695,950869,565 shares of Common Stock, issued in connection with a note and loan agreement dated March 19, 2018, between the Company and Ms. Powers, in each case, subject to certain conditions and limitations on exercisability. Ms. Powers’ beneficial ownership excludes (i)(viii) 1,739,130 shares of Series B Preferred Stock, convertible into 17,391,304 shares of Common Stock and 8,695,652 Class D-2 Warrants to acquire up to an aggregate of 8,695,652 shares of Common Stock, issuable upon conversion of the note and loan agreement dated March 14, 2018, between the Company and Ms. Powers, and (ii)(ix) 173,913 shares of Series B Preferred Stock, convertible into 1,739,130 shares of Common Stock and 869,565 Class D-2 Warrants to acquire up to an aggregate of 869,565 shares of Common Stock, issuable upon conversion of the note and loan agreement dated March 19, 2018, between the Company and Ms. Powers. The Series B Preferred Stock and Class D-2 Warrants to be issued upon conversion of the note and loan agreements, will be subject to certain conditions and limitations on conversion and exercisability, respectively.
(5)
Consists of (i) 172,742 shares of Common Stock held by Mr. Goldman, (ii) 28,38478,862 shares of Common Stock underlying currently exercisable warrants, and (iii) 93,53511,526,867 shares of Common Stock underlying Options held by Mr. Goldman as equity compensation that are vested, or will vest within 60 days of this filing. An aggregate of 10,616,666 of the Options (which are included in the foregoing 11,526,867 Options) are currently vested and immediately exercisable for the purchase of Common Stock at an exercise price of $0.23 per share, and an additional 8,983,334 Options held by Mr. Goldman will vest monthly over a period of 24 months from the date of initial issuance, becoming exercisable for the purchase of Common Stock on the same terms, after they have vested.
(6)
Consists of (i) 10,000 shares of Common Stock held by Dr. Malik and (ii) 5,099,062 shares of Common Stock underlying Options held by Dr. Malik as equity compensation that are vested, or will